Retatrutide has emerged as a new medication in the fight against obesity. This groundbreaking drug, belonging to a dual GLP-1 and GIP receptor agonist, exhibits promising results in clinical trials. By boosting these receptors, Retatrutide suppresses appetite, {promotesglucose regulation, and ultima